Document Detail

MedLine Citation:
PMID:  3478154     Owner:  NLM     Status:  MEDLINE    
Thirty-eight patients with adult acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL) were treated intravenously with (2"-R)-4'-o-Tetrahydropyranyladriamycin (THP) at a dose of 10 mg/m2 for 5 consecutive days. Seven complete and 15 partial responses were observed in 35 evaluable patients (overall response rate, 62.8%). Both antitumor activity and antitumor spectrum were similar to those for doxorubicin. Since the patients who had had chemotherapy previously, including other kinds of anthracycline, responded rather poorly to THP, cross-resistance between THP and other anthracyclines may be present. Leukopenia and thrombocytopenia were dose-limiting factors. Nausea and vomiting episodes were mild, and epilation was also minimal. Although the observation period was short and a cumulative dose was not large enough to evaluate cardiotoxicity, there were no abnormal EKG changes or clinical signs of cardiotoxicity in this study. THP is a potent antitumor agent in the treatment of lymphoid malignancies.
T Takagi; M Oguro
Related Documents :
6896794 - Amsa and peptichemio in the treatment of advances metastatic breast cancer: a phase ii ...
16303864 - Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinor...
16683074 - A phase i and pharmacokinetic study of irofulven and cisplatin administered in a 30-min...
4016774 - Phase ii study of elliptinium in advanced breast cancer.
2159054 - Randomized comparison of two combination regimens versus minimal chemotherapy in nonsma...
23900624 - Treatment strategy for cutaneous apocrine carcinoma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  20     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  1987  
Date Detail:
Created Date:  1987-11-25     Completed Date:  1987-11-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  151-4     Citation Subset:  IM    
Division of Hematology-Chemotherapy, Chiba Cancer Center Hospital, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Doxorubicin / adverse effects,  analogs & derivatives*,  therapeutic use
Leukemia, Lymphoid / drug therapy*,  pathology
Lymphoma, Non-Hodgkin / drug therapy*,  pathology
Middle Aged
Retrospective Studies
Reg. No./Substance:
23214-92-8/Doxorubicin; 72496-41-4/pirarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of antisera against recombinant tumor necrosis factor and the monocyte-derived cytotoxin(s) o...
Next Document:  Growth hormone modifies the growth rate of enzyme-altered hepatic foci in male rats treated accordin...